Lymphokine-activated killer cell susceptibility in epirubicin-resistant and parental human non-small cell lung cancer (NSCLC)

Biologia

Volumn 62, Issue 2, 2007, Pages 232-237

  Ozkan, Aysun ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Antioxidants; Epirubicin HCl; Lymphokine activated killer cells; Non small cell lung cancer

Indexed keywords

EID: 50849089958     PISSN: 00063088     EISSN: 13369563     Source Type: Journal    
DOI: 10.2478/s11756-007-0040-5     Document Type: Article

References (38)

1. Azzi S., Montecucco C. & Richter C. 1975. The use of acetylated ferricytochrome c for the detection of superoxide radicals produced in biological membranes. Biochem. Biophys. Res. Commun. 65: 597-603.
2. Benoist H., Madoulet C., Trentesaux C., Carpentier Y., Joly P., Jardillier J.C. & Desplaces A. 1988. Association of adriamycin-induced resistance to NK-mediated lysis with sialic acid level and immunological reactivity of transferring receptors and glycophorin A. Int. J. Cancer 42: 299-304.
3. Beutler E. 1975. Glutathione peroxidase, pp. 71-73. In: Red Cell Metabolism: A Manual of Biochemical Methods, Grune & Stratton, New York.
4. Bradford M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72: 248-254.
5. Chen S., Wang J., Chen J. & Huang R. 2002. Possible involvement of glutathione and p53 in trichloroethylene and perchloroethylene-induced lipid peroxidation and apoptosis in human lung cancer cells. Free. Radic. Biol. Med. 33: 464-470.
6. Dierickx P.J. 1999. Glutathione-dependent cytotoxicity of the chloroacetanilide herbicides alachlor, metolachor, and propachlor in rat and human hepatoma-derived cultured cells. Cell. Biol. Toxicol. 15: 325-332.
7. Dobbs N.A., Twelwes C.J., Rizzi P., Warvick J.D., Metivier E.M., Williams R. & Johnson P.J. 1994. EPI in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer. Chemother. Pharmacol. 34: 405-410.
8. Furusawa S., Nakana S., Wada M., Chiba H., Takayanagi M., Takayanagi Y. & Sasaki K. 1996. Augmentation of EPI cytotoxicity by cycloheximide. Res. Commun. Mol. Pathol. Pharmacol. 91: 245-252.
9. Grimm E. 1982. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155: 1823-1841.
10. Grunberg E., Eckert K. & Maurer H.R. 1998. Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro. Int. J. Oncol. 12: 957-963.
11. Habig W.H. & Jakoby W.B. 1974. Assay for differentiation of glutathione S-transferases. Methods Enzymol. 77: 398-405.
12. Hao X.Y., Bergh J. & Bordin O. 1994. Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis 15: 1167-1173.
13. Hussain R.F. Nouri A.M.E. & Oliver R.T.D. 1993. A new approach for measurement of cytotoxicity using colorimetric assay. J. Immunol. Methods 160: 89-95.
14. Jansson Ö., Motlagh P.B., Persson M., Henrikson R. & Grankvist K. 1999. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem. Pharmacol. 58: 1801-1806.
15. Kimmura K., Iwai N., Suziki M. & Takahashi Y. 1998. Postsurgical adjuvant immunotherapy against primary non-small cell lung cancer. Nippon Geka Gakkai Zasshi 99: 279-284.
16. Kinnula K., Linnainma K., Raivio K.O. & Kinnula V.L. 1998. Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and EPI toxicity. Br. J. Cancer 77: 1097-1020.
17. Komatsu F. & Ishiguro K. 2003. Lymphokine-activated killer cells can kill target cells not only early killing but also by late killing, and the late killing level against autotumor cell line. Oncol. Res. 13: 235-241.
18. Kotoh S., Naito S., Yokoniza A., Kumazava J., Asakuno K., Kohno K. & Kuvano M. 1994. Inversed expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer. Res. 54: 3248-3252.
19. Kwak J.Y., Han M.K., Choi K.S., Park I.H., Park S.Y., Sohn M.H., Kim U., McGregor J.R., Samlowski W.E. & Yim C.Y. 2000. Cytokines secreted by lymhokine-activated killer cells induced endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell. Immunol. 203: 84-94.
20. Lawrence R.A. & Burk R.F. 1976. Glutathione peroxidase activity in selenium deficient rat liver. Biochem. Biophys. Res. Commun. 71: 952-958.
21. Luck H. 1963. Catalase, pp. 885-894. In: Bergmeyer H.U. (ed.), Methods of Enzymatic Analysis, Academic Press, New York.
22. Matsuzaki I., Suzuki H., Kitamura M., Minamiya Y., Kawai H. & Ogawa J. 2000. Cisplatin induces Fas expression in oesophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology 59: 336-343.
23. McCord J.M. & Fridovich I.J. 1969. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244: 6049-6055.
24. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.
25. Okamoto M., Kasetani H., Kaji R., Godai H., Ohe G., Yoshida H. & Sato M. 1998. cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol. Immunother. 4: 233-241.
26. Ozdamar K. 1995. Statistical data analysis with packaged programs. Ankara: UYTES publications 1: 1-107.
27. Ozkan A., Ayhan A. & Fiskin K. 2004. Combined effect of EPI and lymphokine-activated killer cells on the resistant human breast cancer cells. Cell. Biol. Toxicol. 20: 261-271.
28. Ozkan A. & Fiskin K. 2004. Epirubicin-HCl toxicity in human-liver derived hepatoma G2 cells. Pol. J. Pharmacol. 56: 435-444.
29. Paglia D.E. & Valentine W.N. 1967. Studies on the quantitative and qualitative characterisation of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70: 158-169.
30. Pavarov L.S., Leontieva O.V. & Preobrazhenskaya MN. 1995. Partial circumvention of P-glycoprotein (Pgp)-associated resistance to doxorubicin (Dox) in MCF7/R human breast carcinoma and P388/R murine leukemia cell lines by doxorubicin-14-O-hemiadipate (H-Dox). Russ. J. Bioorg. Chem. 21: 797-803.
31. Ribeiro-Dias F., Barbuto J.A.M., Tsujita M. & Jancar S. 2000. Discrimination between NK and LAK cytotoxicity activities of murine spleen cells by MTT assay: differential inhibition by PGE2 and EDTA. J. Immunol. Methods 241: 121-129.
32. Rihova B., Strohalm J. & Kubackova K. 2002. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J. Control Release 17: 97-114.
33. Runge D., Köhler C., Kostrubsky E.V., Jager D., Lehmann T., Runge M.S., May U. & Stolz D.B. 2000. Reduction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypic reducers in human hepatocytes. Biochem. Biophys. Res. Commun. 27: 333-341.
34. Savas B., Cole P.C., Tsuruo T. & Pross H.F. 1996. P-Glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma. J. Clin. Immunol. 16: 348-357.
35. Siegsmund M.J., Steidler A., Kreukler C., Köhrmann K.U. & Alken P. 1997. Enhanced in vitro cytotoxicity of Idarubicin in rat prostate carcinoma cells. Eur. Urol. 31: 365-370.
36. Synder H.S. & Bredt D.S. 1992. Biological roles of nitric oxide. Sci. Am. 15: 28-34.
37. Tsavaris N., Kosmas C., Vadiaka M., Kanelopoulos P. & Boulamatsis D. 2002. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br. J. Cancer 87: 21-27.
38. Williams C.H. & Kamin H. 1962. Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J. Biol. Chem. 237: 587-595.